Genetic characteristics and prognosis of m6A RNAmethylation regulator in acute myeloid leukemia

Background: To identify the genetic characteristics of m6A RNA methylation regulators in AML and explore their potential value as prognostic markers.Methods: RNA-seq transcriptome data and clinical survival data of acute myeloid leukemia (AML) were downloaded from ICGC and TCGA, gene annotation files were downloaded from GENECODE (1). 13 widely reported m6A RNA alphas were obtained from the literature. The expression of m6A RNA methylation regulators were collected and analized using gene annotation files. The samples were subjected to consistent clustering to obtain two subgroups RM1 and RM2, and the pathological characteristics and survival between the two subgroups were analyzed. Comparative analysis and functional analysis of m6A RNA methylation regulators between subgroups were completed. The STRING database analyzed the interactions between m6A RNA methylation regulators, and Spearman analyzed the correlation of expression of m6A RNA methylation regulators. COX regression analysis and risk scores were used to predict prognosis and pathological characteristics, and risk scores calculated using features were used to predict the prognosis and clinicopathological characteristics of tumor patients.Results: According to the morphological characteristics of AML, the samples were divided into 8 categories (M0 Undifferentiated, M1, M2, M3, M4, M5, M6, M7), and among them, the expression profile and expression heat map of 13 m6A RNA methylation regulators were constructed. Using m6A RNA methylation regulator as a feature vector, consistent clustering of 151 samples yielded two subgroups RM1 and RM2. Among them, the expression of the regulator in RM1 was higher than RM2,and RM2 patients had a longer survival time than RM1. Gene set enrichment analysis found that functional processes such as endothelial-hematopoietic transformation through the Notch pathway were significantly enriched in RM1. The analysis of the KM curve indicates that when the expression of FTO or ALKBH5 or of ZC3H13 was low, the survival time of patients was significantly higher than that with high expression.Conclusion: m6A RNA methylase regulator is not only an independent prognostic marker of AML, but also can predict its clinicopathological characteristics, which has potential value for stratifying prognosis and improving treatment strategies.

[1]  N. Tosic,et al.  The influence of Wilms' tumor 1 gene expression level on prognosis and risk stratification of acute promyelocytic leukemia patients , 2019, International journal of laboratory hematology.

[2]  O. Weinberg,et al.  How I investigate acute myeloid leukemia , 2019, International journal of laboratory hematology.

[3]  C. Hourigan,et al.  MRD evaluation of AML in clinical practice: are we there yet? , 2019, Hematology. American Society of Hematology. Education Program.

[4]  Hui Cao,et al.  m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer , 2019, Bioscience reports.

[5]  R. Al-Temaimi,et al.  The FTO gene polymorphism rs9939609 is associated with obesity and disability in multiple sclerosis patients , 2019, Scientific Reports.

[6]  M. Singh,et al.  Morphological characteristics, cytogenetic profile, and outcome of RUNX1‐RUNX1T1‐positive acute myeloid leukemia: Experience of an Indian tertiary care center , 2019, International journal of laboratory hematology.

[7]  J. Wingard,et al.  Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial. , 2019, JAMA.

[8]  T. Haferlach,et al.  Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia. , 2019, Cancer genetics.

[9]  A. McRee,et al.  Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET) , 2019, Leukemia & lymphoma.

[10]  X. W. Li,et al.  [Regulation of m^(6)A RNA Methylation and Its Effect on Myogenic Differentiation in Murine Myoblasts]. , 2019, Molekuliarnaia biologiia.

[11]  T. Leblanc,et al.  Shifting paradigms in the treatment of older adults with AML. , 2019, Seminars in hematology.

[12]  Esperanza Barrera-Chairez,et al.  Etiology and clinico-hematological profile of pancytopenia: experience of a Mexican Tertiary Care Center and review of the literature , 2019, Hematology.

[13]  C. Strahlendorf,et al.  Enrollment on clinical trials does not improve survival for children with acute myeloid leukemia: A population‐based study , 2018, Cancer.

[14]  A. Schimmer,et al.  The ubiquitin-activating enzyme, UBA1, as a novel therapeutic target for AML , 2018, Oncotarget.

[15]  Yu-Sheng Chen,et al.  Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism , 2018, Cell Research.

[16]  L. Vimercati,et al.  Maternal Exposure to Pesticides, Paternal Occupation in the Army/Police Force, and CYP2D6*4 Polymorphism in the Etiology of Childhood Acute Leukemia , 2018, Journal of pediatric hematology/oncology.

[17]  K. Somasundaram,et al.  Essential role of METTL3-mediated m6A modification in glioma stem-like cells maintenance and radioresistance , 2018, Oncogene.

[18]  Yue Sheng,et al.  METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. , 2017, Cell stem cell.

[19]  Junwei Shi,et al.  Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control , 2017, Nature.

[20]  Rong Yin,et al.  Roles of RNA methylation by means of N6-methyladenosine (m6A) in human cancers. , 2017, Cancer letters.

[21]  John E. J. Rasko,et al.  Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia , 2017, Journal of Hematology & Oncology.

[22]  R. Gregory,et al.  The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells. , 2016, Molecular cell.

[23]  Bifeng Yuan,et al.  Determination of DNA and RNA Methylation in Circulating Tumor Cells by Mass Spectrometry. , 2016, Analytical chemistry.

[24]  J. Rowe,et al.  Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the “3 + 7” induction regimen for acute myeloid leukemia , 2015, American journal of hematology.

[25]  D. Small,et al.  DOCK2 Interacts with FLT3 and Modulates the Survival of FLT3-Expressing Leukemia Cells , 2014, Leukemia.

[26]  O. Elemento,et al.  Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons , 2012, Cell.

[27]  A. Mora,et al.  Parental tobacco smoking and risk of childhood leukemia in Costa Rica: A population-based case-control study. , 2019, Environmental research.

[28]  M. Ansari,et al.  Multiparameter flow cytometry in the diagnosis and management of acute leukemia. , 2011, Archives of pathology & laboratory medicine.